Oct 22, 2018
ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Oct 22, 2018
Novartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
Oct 01, 2018
Digital Landscape: Ankylosing Spondylitis
Aug 13, 2018
Izana Bioscience Initiates Namilumab Phase II Proof-of-Concept Clinical Study in Ankylosing Spondylitis
Jun 28, 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Apr 18, 2018
Musculoskeletal Disorders Pipeline Database 2018: Osteoporosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Ankylosing Spondylitis
Feb 13, 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Jan 09, 2018
Ontario has added Erelzi(TM) (etanercept) to public drug plan for the treatment of multiple inflammatory diseases
Dec 14, 2017
Izana Bioscience Launches as New Clinical-Stage Translational Medicine Company Developing Namilumab in Ankylosing Spondylitis
Dec 07, 2017
Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis
Nov 02, 2017
United States Immunology Drugs Market Overview 2017-2018
Nov 02, 2017
US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - Unit Sales, ASPs, Market Value & Growth Trends
Oct 31, 2017
TNF Inhibitors 2017 - A Pipeline Analysis Report - By Therapy, Roa & Molecule Type
Aug 02, 2017
Uveitis Therapeutics Pipeline Analysis, 2017 - 33 Active Drug Candidates in Different Stages of Development